|Mr. Michael A. Mussallem||Chairman & CEO||2.91M||N/A||1953|
|Mr. Scott B. Ullem||Corp. VP & CFO||1.2M||N/A||1967|
|Mr. Donald E. Bobo Jr.||Corp. VP of Strategy & Corp. Devel.||1.24M||N/A||1962|
|Mr. Larry L. Wood||Corp. VP of Transcatheter Aortic Valve Replacement||1.18M||N/A||1966|
|Ms. Catherine M. Szyman||Corp. VP of Critical Care||1.18M||N/A||1967|
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation’s ISS Governance QualityScore as of October 4, 2019 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 3; Compensation: 3.